DPP-4抑制剂对2型糖尿病患者血清PEDF水平的影响
发布时间：2019-07-03 13:18
【摘要】：目的：为了解2型糖尿病患者血清色素上皮衍生因子(pigment epithelium-derived factor,PEDF)水平以及予以二肽基肽酶-4(DPP-4)抑制剂利格列汀治疗前后PEDF的变化,进一步探讨PEDF与空腹血糖(FGB)、糖化血红蛋白(HbAic).血脂、体重指数(BMI)等指标的相关性。方法：根据OGTT结果将受试者分成两组：2型糖尿病组(39例,男性18例、女性21例),健康者对照组(30例,男性16例、女性14例)。检测2组受试者体重、腰围、BMI、FGB、HbA1C、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、谷丙转氨酶(ALT)、谷草转氨酶(AST),采用酶联免疫吸附法检测血清PEDF的浓度。2型糖尿病组予以口服利格列汀5mg/d共6个月,6个月后复查血清PEDF浓度和实验室指标,并进行统计学分析。结果：(1)在未干预治疗前2型糖尿病组体重、腰围、BMI. FGB及HbAlC与对照组比较分别高11.26%、11.53%、10.31%、63.76%和43.95%,且差异均有统计学意义(均P0.01),2型糖尿病组血清PEDF浓度与对照组相比浓度无显著差异(P=0.584)。(2)PEDF与LDL-C、腰围呈正相关(r=0.416,P0.05；r=0.334,P0.01)。(3)2型糖尿病组经利格列汀治疗后与治疗前相比血清PEDF水平增加,差异有显著性(P0.01),FBG、HbA1C、体重、腰围、BMI、LDL-C均有不同程度的降低,差异有统计学意义(P0.05或P0.01)。结论：初诊2型糖尿病患者治疗前PEDF水平与对照组相似,与LDL-C、腰围呈正相关,经利格列汀治疗后血清PEDF水平上升,提示PEDF可能参与了糖尿病脂质代谢的发生发展。
[Abstract]:Objective: to investigate the level of serum pigment epithelial derived factor (pigment epithelium-derived factor,PEDF) in patients with type 2 diabetes mellitus and the changes of PEDF before and after treatment with dipeptidyl peptidase-4 (DPP-4) inhibitor rieglitine, and to further explore the relationship between PEDF and fasting blood glucose (FGB), glycosylated hemoglobin (HbAic). Correlation of blood lipid, body mass index (BMI) and other indexes. Methods: according to the results of OGTT, the subjects were divided into two groups: type 2 diabetes mellitus group (39 cases, M 18, F 21) and healthy control group (30 cases, M 16, F 14). The body weight, waist circumference, BMI,FGB,HbA1C, total cholesterol (TC), (TG), high density lipoprotein (HDL-C), low density lipoprotein (LDL-C) and glutamic-pyruvic transaminase (ALT), glutamic oxaloacetic transaminase (AST), were measured by enzyme-linked immunosorbent assay (Elisa). After 6 months, serum PEDF concentration and laboratory indexes were reexamined and statistically analyzed. Results: (1) body weight, waist circumference and BMI. in type 2 diabetes mellitus group before intervention treatment. Compared with the control group, FGB and HbAlC were 11.26%, 11.53%, 10.31%, 63.76% and 43.95%, respectively, and the difference was statistically significant (P 0.01). There was no significant difference in serum PEDF concentration between type 2 diabetes mellitus group and control group (P 鈮，
本文编号：2509422
[Abstract]:Objective: to investigate the level of serum pigment epithelial derived factor (pigment epithelium-derived factor,PEDF) in patients with type 2 diabetes mellitus and the changes of PEDF before and after treatment with dipeptidyl peptidase-4 (DPP-4) inhibitor rieglitine, and to further explore the relationship between PEDF and fasting blood glucose (FGB), glycosylated hemoglobin (HbAic). Correlation of blood lipid, body mass index (BMI) and other indexes. Methods: according to the results of OGTT, the subjects were divided into two groups: type 2 diabetes mellitus group (39 cases, M 18, F 21) and healthy control group (30 cases, M 16, F 14). The body weight, waist circumference, BMI,FGB,HbA1C, total cholesterol (TC), (TG), high density lipoprotein (HDL-C), low density lipoprotein (LDL-C) and glutamic-pyruvic transaminase (ALT), glutamic oxaloacetic transaminase (AST), were measured by enzyme-linked immunosorbent assay (Elisa). After 6 months, serum PEDF concentration and laboratory indexes were reexamined and statistically analyzed. Results: (1) body weight, waist circumference and BMI. in type 2 diabetes mellitus group before intervention treatment. Compared with the control group, FGB and HbAlC were 11.26%, 11.53%, 10.31%, 63.76% and 43.95%, respectively, and the difference was statistically significant (P 0.01). There was no significant difference in serum PEDF concentration between type 2 diabetes mellitus group and control group (P 鈮，
本文编号：2509422
本文链接：https://www.wllwen.com/yixuelunwen/nfm/2509422.html
最近更新
教材专著
